The history of GeNeuro

2018

  • GeNeuro announces final 1-year results from its 270-patient CHANGE-MS study on RRMS patients, confirming a robust and coherent impact on the key MRI markers associated with disease progression. Moreover, the benefits are also observed in patients with lower inflammatory burden, which are not served by present anti-inflammatory treatments.

  • Despite positive results, Servier decides to return worldwide rights ex US and Japan for temelimab in MS due to R&D strategic reasons and Servier’s international development priorities. GeNeuro engages in new partnership discussions for its lead MS program.

  • GeNeuro announces 6-month results of its T1D trial confirming the safety of this approach, the primary endpoint of the study in this new patient population, as well as pharmacodynamic markers such as a reduction in the number of hypoglycemic episodes.

  • Based on the joint preclinical effort started in 2017, GeNeuro acquires from the US NIH all IP rights to develop a new treatment against Amyotrophic Lateral Sclerosis based on neutralizing the pathogenic HERV-K protein. GeNeuro launches a formal preclinical effort aiming to obtain an IND by mid-2020. 

  • Signing of a financing agreement with GNEH SAS, a subsidiary of Institut Mérieux, to establish a €7.5 million credit line, which extends the company runway with all ongoing programs until mid-2020.

2017

  • Finalization of the recruitment of patients in the study of Phase IIb CHANGE-MS study in multiple sclerosis, ahead of the schedule, and launch of the open-label extension study (ANGEL-MS),  also funded by Servier, allowing patients who finished the CHANGE-MS study to extend their treatment for two additional years.

  • GeNeuro announces treatment of the first patient in a Phase IIa study with temelimab in type 1 diabetes. This Australian clinical trial plans to recruit 60 adult patients in more than 10 centers.

  • GeNeuro signs an agreement with the U.S. NIH to develop a new treatment option against Amyotrophic Lateral Sclerosis. This partnership focuses on antibodies targeting the HERV-K Env protein, a potential cause of the sporadic form of the disease, which accounts for more than 90% of the ALS population.

  • GeNeuro Announces 6-month results from its 270-patient CHANGE-MS study on RRMS patients, failing the primary endpoint measuring MRI inflammation markers, but showing promising data on secondary markers of neurodegeneration, to be confirmed by one-year results.

2016

  • GeNeuro's IPO on Euronext Paris, raising 33 M€ in order to expedite its clinical development in the United States and in new indications, such as type-1 diabetes.

  • GeNeuro Announces treatment of first patients in its study of phase IIb in MS. The CHANGE-MS clinical trial, funded by Servier, targets a-260 patient recruitment in 13 European countries.

2015

  • GeNeuro SA launches a Phase IIb trial in multiple sclerosis.

  • GeNeuro SA announces the completion of a pharmacology study testing high doses of temelimab.

2014

  • GeNeuro and Servier sign a collaboration agreement for the development of a medicine targeting a potential causal factor of multiple sclerosis.

  • GeNeuro SA announces the completion of the Phase IIa trial with good safety results and promising pharmacodynamic responses.

2013 

  • The Swiss Medicine Agency authorizes GeNeuro to undertake a Phase IIa trial with a repeated-dose extension for a total of 12 months.

  • GeNeuro SA announces the completion of a phase IIa clinical trial with temelimab. During the study, MS patients received the monoclonal antibody temelimab at two different doses.

  • GeNeuro confirms the scientific interest in developing temelimab as a treatment for CIDP during a scientific advice meeting with the European Medicines Agency (EMA).

2012

  • GeNeuro SA announces the launch of a Phase IIa clinical study with temelimab. The randomized placebo-controlled Phase IIa study tested single ascending doses of temelimab in patients with multiple sclerosis for the first time.

2011

  • GeNeuro SA announces the completion of its Phase I clinical study with temelimab. The randomized, double-blind, placebo-controlled, Phase I study of single ascending intravenous doses of temelimab in healthy volunteers demonstrated that temelimab is well tolerated.

  • Swissmedic, the Swiss medicines agency, authorizes GeNeuro to start a Phase I trial of the monoclonal antibody temelimab in healthy volunteers. Temelimab is developed for the treatment of multiple sclerosis.

  • GeNeuro's 5th anniversary.

2010

  • GeNeuro obtains a positive opinion from a German regulatory scientific committee, the Paul Ehrlich Institute, regarding the pre-clinical package for its lead monoclonal antibody temelimab, a humanized monoclonal antibody targeting a human endogenous retrovirus, to treat multiple sclerosis.

  • GeNeuro Innovation SAS obtains the status of Small and Medium Enterprise (SME) awarded by the European Medicines Agency.

  • GeNeuro Innovation SAS opens a laboratory facility in Archamps.en Haute Savoie (France).

2009

  • GeNeuro SA moves to its new location in Geneva / Plan-les-Ouates (Switzerland).

  • The French subsidiary GeNeuro Innovation SAS is established in Lyon (France).

2008

  • In August 2008, GeNeuro obtains funding from Eclosion and Institut Mérieux to expand its operations and advance its drug portfolio towards clinical development.

2006

  • GeNeuro SA is founded by Dr Hervé Perron, Dr Christophe Mérieux and Jesús Martin-Garcia, with the help of bioMérieux, a leading French diagnostics company, and Eclosion, a Swiss start-up incubator that supports the development of projects in life sciences.